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Abstract
Increasing evidence is emerging that the
measurement of circulating biomarkers may
be clinically useful for diagnosing and mon-
itoring sepsis. Eight members of AcEMC
(Academy of Emergency Medicine and
Care) and eight members of SIBioC (Italian
Society of Clinical Biochemistry and
Laboratory Medicine) were identified by
the two scientific societies for producing a
consensus document aimed to define practi-
cal recommendations about the use of bio-
markers for diagnosing of sepsis and man-
aging antibiotic therapy in the emergency
department (ED). The cumulative opinions
allowed defining three grade A recommen-
dations (i.e., highly recommended indica-
tions), entailing ordering modality (bio-
markers always available on prescription),
practical use (results should be interpreted
according to clinical information) and test
ordering defined according to biomarker
kinetics. Additional grade B recommenda-
tions (i.e., potentially valuable indications)
entailed general agreement that biomarkers
assessment may be of clinical value in the
diagnostic approach of ED patients with
suspected sepsis, suggestion for combined
assessment of procalcitonin (PCT) and C-
reactive protein (CRP), free availability of
the selected biomarker(s) on prescription,
adoption of diagnostic threshold prioritizing
high negative predictive value, preference
for more analytically sensitive techniques,
along with potential clinical usefulness of
measuring PCT for monitoring antibiotic
treatment, with serial testing defined
according to biomarker kinetics. PCT and
CRP were the two biomarkers that received
the largest consensus as sepsis biomarkers
(grade B recommendation), and a grade B
recommendation was also reached for rou-
tine assessment of blood lactate. The assess-
ment of biomarkers other than PCT and
CRP was discouraged, with exception of
presepsin for which substantial uncertainty
in favor or against remained.
Introduction
Around the 700 BC the ancient Greeks
identified with the term sηψiζ (i.e., sepsis),
intended as decomposition or putrefaction, a
severe medical condition carrying a high risk
of infection-related mortality.1 Despite this
rather long history, clinicians felt the need for
a more precise definition of the syndrome
only in the last decades of the past century,
and three essential - though not fully concor-
dant - milestones were set in 1992, 2003 and
2016.2 After the third international conference
on sepsis and septic shock, sepsis was hence
defined as a life-threatening organic dysfunc-
tion caused by a disordered response of the
host to an infection.3 Notably, this definition
brings back to the illuminating intuition of Sir
William Osler, who had already written at the
beginning of the 1900s that with rare excep-
tions, the patient seems to die because of the
body’s reaction to infection rather than
because of the infection itself.4 The term sep-
tic shock refers instead to a particular type of
sepsis, whose deep circulatory, cellular and
metabolic abnormalities are associated with a
greater risk of mortality than sepsis alone.
As regards the epidemiology, recent data
shows that the frequency of sepsis is approx-
imately 2% in the general hospital popula-
tion, but can increase up to 6-30% in patients
admitted to the intensive care unit (ICU).5
Nevertheless, these estimates are influenced
by considerable heterogeneity depending on
geographical setting, type of facility and hos-
pital department, since more than 50% of
patients with severe sepsis are admitted to the
ICU with a considerably high mortality rate
(i.e., between 28-50%).6 The recent findings
of an observational study in the United States
attest that the frequency of sepsis in hospital-
ized patients will approximately increase by
9% per year.7 In the emergency room setting,
an Australian prospective study has recently
shown that most (i.e., over 97%) of patients
admitted with severe sepsis in the ICU had
been earlier triaged in the emergency depart-
ment (ED).8 Notably, sepsis could be identi-
fied in only 53% of these patients while in the
ED, thus emphasizing the need to further
refine the diagnostic tools available to the
emergency physicians.
The recent conclusions of the Sepsis-3
group substantially simplified the classifica-
tion, eliminating the subgroups of SIRS
(Systemic Inflammatory Response
Syndrome) and severe sepsis, thus maintain-
ing only the two categories of sepsis and sep-
tic shock.3 The SIRS has hence disappeared
as an autonomous condition, since it is now
considered an appropriate physiological
response to a large number of infectious and
non-infectious conditions and remains as a
set of signs and symptoms characterizing sep-
sis only with the concomitant presence of
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organ damage identified by attributing at least
two points to the SOFA (Sequential [Sepsis-
Related] Organ Failure Assessment) score.3
Since the parameters of both SIRS and SOFA
scores also include laboratory tests, the
authors have searched for, and have identi-
fied, a simplified clinical system which
allows a high degree of suspicion and atten-
tion from the triage. This simplified system
involves the assessment of three simple
parameters, i.e., respiratory rate, altered men-
tal status and arterial pressure. The combina-
tion of these three parameters was included in
a simplified and fast score, called qSOFA
(quick-SOFA) score. The task force suggests
that the qSOFA criteria, when positive,
should allow to early detecting organ damage
and infection sources, as well as initiating, or
early reinforcing, the therapy.3 According to
the conclusions of the task force, the qSOFA
is not intended as a diagnostic criterion, but
rather a sort of red flag for triage.
Interestingly, the definition of sepsis iron-
ically resembles that of time; the closer we
get, the farther we are. The conclusions of the
Sepsis-3 task force have already raised criti-
cisms and demands for revision and/or fur-
ther validation. One of the main criticisms is
that the validation of qSOFA criteria has been
obtained retrospectively in ICU patients, thus
lacking reliable data on large populations of
patients evaluated in the ED and then hospi-
talized. Therefore, prospective validation is
needed in these care settings.9 A first observa-
tional study conducted outside the ICU does
not seemingly support the usefulness of
qSOFA, which has a significantly lower diag-
nostic performance than the MEWS
(Modified Early Warning Score) and NEWS
(National Early Warning Score), which are
already widely used in many emergency
rooms.10 According to the new definitions,
sepsis and septic shock are treated as syn-
dromes and not as specific diseases. The chal-
lenges to establishing whether sepsis may
actually be secondary to an infection, and
which is the etiology and the site of the infec-
tion, still represent important limitations for
clinical use in the individual patient.
Some clinical conditions mimicking sep-
sis may be due to non-infectious conditions,
such as acute pancreatitis, major trauma,
burns and venous thromboembolism.9 The
search for the septic source, when not imme-
diately apparent, is a priority, which can be
somehow supported by bedside ultrasound.11
Therefore, there is ongoing research for iden-
tifying other tools which may support clini-
cians not only for identifying patients pre-
senting with sepsis, but also for defining the
potential etiology and stratifying the risk ear-
lier and more accurately, since the outcome is
strongly influenced by early diagnosis and
appropriate and timely treatment.12,13 The
                                                                                                                Opinion Report
Table 1. Definition of the strength of recommendations, in accordance with the National
Guidelines Program.
A         Highly recommended indication: Indicates a specific recommendation supported by good-quality
           scientific evidence
B         Doubts remain that a specific indication may always be recommended, but there is general 
           consensus that it should be carefully considered
C         There is substantial uncertainty in favor of or against this recommendation
D         The indication is discouraged
E         Highly discouraged indication
                                                                       [Emergency Care Journal 2017; 13:6877]                                                      [page 43]
Figure 1. Electronic search strategy conducted on the three major scientific databases
(Medline with PubMed interface, Scopus and Web of Science), using the keywords sepsis
AND biomarker (s) AND meta-analysis, without language and/or date restrictions.
No
n c
om
me
rci
al 
us
e o
nly
                             Opinion Report
Ta
bl
e 
2.
 M
et
a-
an
al
ys
es
 a
bo
ut
 b
io
m
ar
ke
rs
 f
or
 t
he
 d
ia
gn
os
is
 o
f 
se
ps
is
.
Au
th
or
s 
   
   
   
   
   
B
io
m
ar
ke
rs
   
   
   
   
   
 C
ut
-o
ff
   
   
   
   
   
   
   
   
  S
tu
dy
 a
nd
 p
op
ul
at
io
ns
   
   
   
   
   
   
   
   
   
   
   
 S
et
ti
ng
   
   
   
   
   
   
  H
et
er
og
en
ei
ty
   
   
   
   
   
   
   
   
   
   
   
  R
es
ul
ts
Ad
ul
ts
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Uz
za
n 
et
 a
l., 
20
06
17
    
    
   P
CT
, C
RP
    
    
    
    
  P
CT
: 0
.6-
5.0
 n
g/m
L;
   
    
    
    
    
    
    
  3
3 s
tu
di
es
, 3
94
3 p
at
ie
nt
s  
    
    
    
    
    
    
    
    
Pa
tie
nt
s i
n 
in
te
ns
ive
 ca
re
   
    
    
    
    
Si
gn
ifi
ca
nt
    
    
    
    
    
    
    
   P
CT
: A
UC
, 0
.78
 (9
5%
 C
I, 
0.7
1-
0.8
4)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  C
RP
: 3
9-
18
0 m
g/L
    
    
    
    
    
(p
ro
sp
ec
tiv
e/
ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
    
    
    
    
    
fo
r t
ra
um
a/s
ur
ge
ry
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   s
en
sit
ivi
ty,
 0.
42
-1
.00
; s
pe
cif
ici
ty,
 0.
48
-1
.00
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 C
RP
: A
UC
, 0
.71
 (9
5%
 C
I, 
0.6
4-
0.7
6)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.3
5-
1.0
0; 
sp
ec
ifi
cit
y, 
0.1
8-
0.8
5
Ta
ng
 et
 a
l., 
20
07
18
    
    
    
    
  P
CT
    
    
    
    
    
    
    
0.5
0-
20
 n
g/m
L
    
    
    
    
    
    
    
    
 18
 st
ud
ie
s, 
20
97
 p
at
ie
nt
s 
    
    
    
    
    
Pa
tie
nt
s i
n 
in
te
ns
ive
 ca
re
 (1
4 s
tu
di
es
) 
    
  S
ign
ifi
ca
nt
    
    
    
    
   P
CT
: A
UC
, 0
.78
; s
en
sit
ivi
ty,
 0.
71
 (9
5%
 C
I, 
67
-7
6)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
) 
    
  a
nd
/o
r e
m
er
ge
nc
y d
ep
ar
tm
en
t (
4 s
tu
di
es
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
sp
ec
ifi
cit
y, 
0.7
1 (
95
% 
CI
, 6
7-
76
)
W
u 
et
 a
l., 
20
12
19
    
    
    
    
sT
RE
M
-1
    
    
    
    
    
  4
0-
35
00
 p
g/m
L 
    
    
    
    
    
    
    
    
11
 st
ud
ie
s, 
17
95
 p
at
ie
nt
s 
    
    
    
    
    
  P
at
ie
nt
s w
ith
 sy
st
em
ic 
in
fla
m
m
at
io
n 
    
    
Si
gn
ifi
ca
nt
    
    
 sT
RE
M
-1
: A
UC
, 0
.87
 (9
5%
 C
I, 
0.8
4 t
o 
0.8
9)
; s
en
sit
ivi
ty,
 0.
79
;
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
)  
    
    
    
    
    
    
    
    
    
    
    
  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  s
pe
cif
ici
ty,
 0.
80
 (s
en
sit
ivi
ty,
 0.
83
 e
 sp
ec
ifi
cit
y, 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
0.6
8 i
n 
em
er
ge
nc
y d
ep
ar
tm
en
t)
W
ac
ke
r e
t a
l., 
20
13
20
    
    
    
 P
CT
    
    
    
    
    
    
 0.
10
-1
5.7
5 n
g/m
L 
    
    
    
    
    
    
    
  3
0 s
tu
di
es
, 3
24
4 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
   P
at
ie
nt
s w
ith
 sy
st
em
ic
    
    
    
    
    
  S
ign
ifi
ca
nt
    
    
    
    
    
    
    
   P
CT
: A
UC
, 0
.85
 (9
5%
 C
I, 
0.8
1-
0.8
8)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
    
    
    
    
    
    
 i
nf
lam
m
at
io
n 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   s
en
sit
ivi
ty,
 0.
77
; s
pe
cif
ici
ty,
 0.
79
Le
e 
et
 a
l., 
20
13
21
    
    
    
    
    
PC
T 
    
    
    
    
    
PC
T: 
0.2
0-
0.5
1 n
g/m
L;
   
    
    
    
    
    
    
  4
 st
ud
ie
s, 
76
0 p
at
ie
nt
s  
    
    
    
    
    
    
    
 E
ld
er
ly 
po
pu
lat
io
n 
(≥
65
 ye
ar
s)
    
    
    
  S
ign
ifi
ca
nt
    
    
    
    
    
    
    
   P
CT
: A
UC
, 0
.89
 (9
5%
 C
I, 
0.8
6-
0.9
2)
;
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  C
RP
: 3
0-
17
5 m
g/L
    
    
    
    
    
    
    
(o
nl
y p
ro
sp
ec
tiv
e 
st
ud
ie
s)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.8
3; 
sp
ec
ifi
cit
y, 
0.8
3 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 (s
en
sit
ivi
ty,
 0.
97
 e
 sp
ec
ifi
cit
y, 
0.6
1 i
n 
em
er
ge
nc
y d
ep
ar
tm
en
t)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
CR
P:
 A
UC
, n
on
-c
alc
ul
at
ed
; s
en
sit
ivi
ty,
 0.
91
; s
pe
cif
ici
ty,
 0.
36
Ho
eb
oe
re
t a
l., 
20
15
22
    
    
  P
CT
    
    
    
    
    
    
   0
.15
-1
7 n
g/m
L 
    
    
    
    
    
    
    
   5
8 s
tu
di
es
, 1
65
14
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
  U
ns
el
ec
te
d 
po
pu
lat
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
    
    
  P
CT
: A
UC
, 0
.79
; s
en
sit
ivi
ty,
 0.
76
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   (
op
tim
al:
 0.
5 n
g/m
L)
    
    
    
    
 (p
ro
sp
ec
tiv
e/
ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 sp
ec
ifi
cit
y, 
0.8
0 (
AU
C 
0.7
8, 
se
ns
iti
vit
y, 
0.7
6 e
 sp
ec
ifi
cit
y, 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
0.6
8 i
n 
em
er
ge
nc
y d
ep
ar
tm
en
t)
Re
n 
et
 a
l., 
20
15
23
    
    
    
    
   P
CT
    
    
    
    
    
    
    
 0.
5-
30
 n
g/m
L 
    
 8 
st
ud
ie
s, 
56
6 p
at
ie
nt
s (
no
n-
sp
ec
ifi
ed
 ty
pe
s o
f s
tu
di
es
)  
    
    
    
  B
ur
n 
pa
tie
nt
s 
    
    
    
    
    
    
    
 S
ign
ifi
ca
nt
  P
CT
: A
UC
, 0
.92
 (9
5%
 C
I, 
0.8
1-
0.8
8)
; s
en
sit
ivi
ty,
 0.
74
; s
pe
cif
ici
ty,
 0.
88
W
an
ge
t a
l., 
20
15
24
    
    
    
  n
CD
64
    
    
    
    
    
    
    
  A
rb
itr
ar
y 
    
   8
 st
ud
ie
s, 
19
86
 p
at
ie
nt
s (
no
n-
sp
ec
ifi
ed
 ty
pe
s o
f s
tu
di
es
) 
    
 U
ns
el
ec
te
d 
po
pu
lat
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
 n
CD
64
: A
UC
, 0
.95
 (±
0.0
2)
; s
en
sit
ivi
ty,
 0.
76
; s
pe
cif
ici
ty,
 0.
85
W
u 
et
 a
l.,
20
15
25
    
    
    
   P
re
se
ps
in
    
    
    
    
    
 31
7-
70
0 p
g/m
L 
    
    
9 s
tu
di
es
, 2
15
9 p
at
ie
nt
s (
on
ly 
pr
os
pe
ct
ive
 st
ud
ie
s)
    
    
    
Un
se
le
ct
ed
 p
op
ul
at
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
 P
re
se
ps
in
: A
UC
, 0
.89
 (9
5%
 C
I, 
0.8
4-
0.9
4)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.7
8; 
sp
ec
ifi
cit
y, 
0.8
3
To
ng
et
 a
l., 
20
15
26
    
    
    
Pr
es
ep
sin
    
    
    
    
    
 31
7-
86
4 p
g/m
L 
    
    
    
    
    
    
    
    
11
 st
ud
ie
s, 
31
06
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
   U
ns
el
ec
te
d 
po
pu
lat
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
 P
re
se
ps
in
: A
UC
, 0
.89
 (9
5%
 C
I, 
0.8
6-
0.9
2)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
(1
0 p
ro
sp
ec
tiv
e 
st
ud
ie
s, 
1 c
as
e-
co
nt
ro
l s
tu
dy
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 se
ns
iti
vit
y, 
0.8
3; 
sp
ec
ifi
cit
y, 
0.8
1
Ch
en
gf
en
 et
 a
l., 
20
15
27
    
    
 P
CT
    
    
    
    
    
    
  0
.1-
15
.75
 n
g/m
L 
    
    
    
    
    
    
    
   2
4 s
tu
di
es
, 3
10
7 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
   U
ns
el
ec
te
d 
po
pu
lat
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
 P
CT
: A
UC
 in
 n
on
-s
ur
gic
al 
pa
tie
nt
s, 
0.8
0 (
95
% 
CI
, 0
.75
-0
.85
); 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  A
UC
 in
 su
rg
ica
l p
at
ie
nt
s, 
0.7
1 (
95
% 
CI
, 0
.65
-0
.81
); 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.7
4; 
sp
ec
ifi
cit
y, 
0.7
0
Zh
an
g e
t a
l., 
20
15
28
    
    
  P
re
se
ps
in
    
    
    
    
    
 31
7-
72
9 p
g/m
L 
    
    
    
    
    
    
    
    
 8 
st
ud
ie
s, 
18
15
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
Pa
tie
nt
s w
ith
 sy
st
em
ic 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
 P
re
se
ps
in
: A
UC
, 0
.89
 (9
5%
 C
I, 
0.8
6-
0.9
2)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
on
ly 
pr
os
pe
ct
ive
 st
ud
ie
s)
    
    
    
    
    
    
    
    
    
    
   i
nf
lam
m
at
io
n 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.8
6; 
sp
ec
ifi
cit
y, 
0.7
8 (
se
ns
iti
vit
y, 
0.8
5 e
 sp
ec
ifi
cit
y, 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
0.7
9 i
n 
em
er
ge
nc
y d
ep
ar
tm
en
t)
Zh
an
g e
t a
l., 
20
15
29
    
    
  P
re
se
ps
in
    
    
    
    
    
 31
7-
72
9 p
g/m
L 
    
    
    
    
    
    
    
    
11
 st
ud
ie
s, 
30
52
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
   U
ns
el
ec
te
d 
po
pu
lat
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
  P
re
se
ps
in
: A
UC
, 0
.88
 (9
5%
 C
I, 
0.8
4-
0.9
0)
; s
en
sit
ivi
ty,
 0.
83
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
)  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 sp
ec
ifi
cit
y, 
 0.
78
 (s
lig
ht
ly 
lo
we
r i
n 
em
er
ge
nc
y d
ep
ar
tm
en
t)
Zh
en
ge
t a
l.,
20
15
30
    
    
  P
re
se
ps
in
    
    
    
    
    
 31
7-
72
9 p
g/m
L 
    
    
    
    
    
    
    
    
 8 
st
ud
ie
s, 
17
57
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
Pa
tie
nt
s w
ith
 sy
st
em
ic 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
 P
re
se
ps
in
: A
UC
, 0
.86
 (±
0.0
2)
; s
en
sit
ivi
ty,
 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  (
on
ly 
pr
os
pe
ct
ive
 st
ud
ie
s)
    
    
    
    
    
    
    
    
    
    
   i
nf
lam
m
at
io
n 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  0
.77
; s
pe
cif
ici
ty,
 0.
73
Ch
en
 et
 a
l.,
20
16
31
    
    
    
    
 L
BP
    
    
    
    
    
    
  2
7.3
-6
4.4
 µ
g/m
L 
    
    
   8
 st
ud
ie
s, 
16
84
 p
at
ie
nt
s (
pr
os
pe
ct
ive
 st
ud
ie
s)
    
    
    
    
Un
se
le
ct
ed
 p
op
ul
at
io
n 
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
LB
P;
 A
UC
, 0
.68
 (9
5%
 C
I, 
0.6
4-
0.7
2)
; s
en
sit
ivi
ty,
 0.
64
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
sp
ec
ifi
cit
y, 
0.6
3 (
se
ns
iti
vit
y, 
0.7
0 e
 sp
ec
ifi
cit
y, 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 0.
56
 in
 e
m
er
ge
nc
y d
ep
ar
tm
en
t o
r g
en
er
al 
m
ed
ici
ne
)
M
a e
t a
l., 
20
16
32
    
    
    
IL
-6
, P
CT
, C
RP
    
    
   I
L-
6, 
0.0
2-
10
00
 p
g/m
L;
   
    
    
    
    
    
   2
2 s
tu
di
es
, 2
68
0 p
at
ie
nt
s 
    
    
    
    
    
  P
at
ie
nt
s w
ith
 sy
st
em
ic 
in
fla
m
m
at
io
n 
    
    
Si
gn
ifi
ca
nt
    
    
    
IL
-6
: A
UC
, 0
.80
 (±
0.0
3)
; s
en
sit
ivi
ty,
 0.
68
; s
pe
cif
ici
ty,
 0.
73
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
PC
T, 
0.1
-6
.0 
ng
/m
L:
 C
RP
,  
    
    
    
(p
ro
sp
ec
tiv
e/
ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 P
CT
: A
UC
, 0
.83
 (±
0.0
3)
; s
en
sit
ivi
ty,
 0.
78
; s
pe
cif
ici
ty,
 0.
67
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   1
1-
40
0 m
g/L
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  C
RP
: A
UC
; 0
.71
 (±
0.0
2)
; s
en
sit
ivi
ty,
 0.
78
; s
pe
cif
ici
ty,
 0.
67
Co
nt
in
ue
d 
on
 n
ex
t p
ag
e
[page 44]                                                       [Emergency Care Journal 2017; 13:6877]
No
n c
om
me
rci
al 
us
e o
nly
                                    [Emergency Care Journal 2017; 13:6877]                                                      [page 45]
                                                                                                                Opinion Report
co
nt
in
ue
d 
fr
om
 p
re
vi
ou
s 
pa
ge
.
Au
th
or
s 
   
   
   
   
   
B
io
m
ar
ke
rs
   
   
   
   
   
 C
ut
-o
ff
   
   
   
   
   
   
   
   
  S
tu
dy
 a
nd
 p
op
ul
at
io
ns
   
   
   
   
   
   
   
   
   
   
   
 S
et
ti
ng
   
   
   
   
   
   
  H
et
er
og
en
ei
ty
   
   
   
   
   
   
   
   
   
   
   
  R
es
ul
ts
Ad
ul
ts
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Li
u 
et
 a
l., 
20
16
33
    
    
   P
CT
, C
RP
, I
L-
6, 
    
    
 IQ
R:
 P
CT
, 0
.5-
1.7
 g/
m
L;
   
    
    
    
    
    
 86
 st
ud
ie
s, 
10
43
8 p
at
ie
nt
s 
    
    
    
    
    
 P
at
ie
nt
s w
ith
 sy
st
em
ic 
in
fla
m
m
at
io
n 
    
    
Si
gn
ifi
ca
nt
    
    
 P
CT
: A
UC
, 0
.85
 (0
.82
-0
.88
); 
se
ns
iti
vit
y, 
0.7
9; 
sp
ec
ifi
cit
y, 
0.7
8
    
    
    
    
    
    
    
    
  s
TR
EM
-1
, p
re
se
ps
in
,  
    
  C
RP
, 3
8-
14
0 m
g/L
;   
    
    
    
    
    
(n
on
-s
pe
cif
ie
d 
typ
es
 o
f s
tu
di
es
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 C
RP
: A
UC
, 0
.77
 (0
.73
-0
.81
); 
se
ns
iti
vit
y, 
0.7
5; 
sp
ec
ifi
cit
y, 
0.6
7
    
    
    
    
    
    
    
    
    
    
   L
BP
, n
CD
64
    
    
    
    
IL
-6
, 7
5-
22
0 p
g/m
L;
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 IL
-6
: A
UC
, 0
.79
 (0
.75
-0
.82
); 
se
ns
iti
vit
y, 
0.7
2; 
sp
ec
ifi
cit
y, 
0.7
3
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   s
TR
EM
-1
, 3
5-
59
4 p
g/m
L;
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
sT
RE
M
-1
: A
UC
, 0
.85
 (0
.82
-0
.88
); 
se
ns
iti
vit
y, 
0.7
8; 
sp
ec
ifi
cit
y, 
0.7
8
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 p
re
se
ps
in
, 4
15
-6
47
 p
g/m
L;
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 P
re
se
ps
in
: A
UC
, 0
.88
 (0
.85
-0
.90
); 
se
ns
iti
vit
y, 
0.8
4; 
sp
ec
ifi
cit
y, 
0.7
7
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
LB
P, 
24
.3-
32
 µ
g/m
L;
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 L
BP
: A
UC
, 0
.71
 (0
.67
-0
.75
); 
se
ns
iti
vit
y, 
0.6
2; 
sp
ec
ifi
cit
y, 
0.7
0
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  n
CD
64
, n
on
-s
pe
cif
ie
d 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  n
CD
64
: A
UC
, 0
.96
 (0
.94
-0
.97
); 
se
ns
iti
vit
y, 
0.8
7; 
sp
ec
ifi
cit
y, 
0.9
3
Ni
 et
 a
l., 
20
16
34
    
    
    
    
    
su
PA
R 
    
    
    
    
    
    
 2.
7-
9.5
 n
g/m
L 
    
    
    
    
    
    
    
    
  7
 st
ud
ie
s, 
10
62
 p
at
ie
nt
s 
    
    
    
    
    
    
 P
at
ie
nt
s w
ith
 an
d 
wi
th
ou
t s
ys
te
m
ic 
    
    
 S
ign
ifi
ca
nt
    
    
    
  s
uP
AR
: A
UC
, 0
.82
 (9
5%
 C
I, 
0.7
8-
0.8
5)
; s
en
sit
ivi
ty,
 0.
67
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 (4
 st
ud
ie
s a
nd
 48
12
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
in
fla
m
m
at
io
n 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  s
pe
cif
ici
ty,
 0.
80
 (f
or
 d
iag
no
sin
g s
ep
sis
 in
 p
at
ie
nt
s w
ith
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 w
ith
 sy
st
em
ic 
in
fla
m
m
at
io
n;
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   
sy
st
em
ic 
in
fla
m
m
at
io
n:
 A
UC
, 0
.68
 e
 95
% 
CI
, 0
.64
-0
.72
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   6
 p
ro
sp
ec
tiv
e 
st
ud
ie
s a
nd
   
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 se
ns
iti
vit
y, 
0.6
1; 
sp
ec
ifi
cit
y, 
0.8
2)
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   1
 ca
se
-c
on
tro
l s
tu
dy
) 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   
Ca
br
al 
et
 a
l., 
20
16
35
    
    
    
   P
CT
    
    
    
    
    
    
    
0.5
-5
.0 
ng
/m
L 
14
 st
ud
ie
s, 
83
0 p
at
ie
nt
s (
pr
os
pe
ct
ive
/ca
se
- c
on
tro
l s
tu
di
es
) 
    
    
   B
ur
n 
pa
tie
nt
s 
    
    
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
PC
T: 
AU
C,
 0.
87
 (±
0.0
4)
; s
en
sit
ivi
ty,
 0.
77
; s
pe
cif
ici
ty,
 0.
65
Ne
on
at
es
Yu
 et
 a
l., 
20
10
36
    
    
    
    
 P
CT
, C
RP
    
    
    
    
    
  N
on
-s
pe
cif
ie
d 
    
    
    
    
    
    
    
    
22
 st
ud
ie
s, 
28
36
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
    
   N
eo
na
te
s 
    
    
    
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
   P
CT
 fo
r n
eo
na
ta
l s
ep
sis
: A
UC
, 0
.77
; s
en
sit
ivi
ty,
 0.
72
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   s
pe
cif
ici
ty,
 0.
77
. C
RP
 fo
r p
ro
ba
bl
e 
ne
on
at
al 
se
ps
is:
 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   A
UC
, 0
.88
; s
en
sit
ivi
ty,
 0.
81
; s
pe
cif
ici
ty,
 0.
92
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 C
RP
 fo
r n
eo
na
ta
l s
ep
sis
: A
UC
, 0
.75
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.5
5, 
sp
ec
ifi
cit
y, 
0.8
5. 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
CR
P 
fo
r p
ro
ba
bl
e 
ne
on
at
al 
se
ps
is:
 A
UC
, 0
.81
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.7
7, 
sp
ec
ifi
cit
y, 
0.7
9
Vo
ul
ou
m
an
ou
 et
 a
l., 
20
11
37
 P
CT
    
    
    
    
    
    
  0
.50
-5
.75
 n
g/m
L 
    
    
    
    
    
    
    
   1
6 s
tu
di
es
, 1
95
9 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
    
   N
eo
na
te
s 
    
    
    
    
    
    
    
    
 S
ign
ifi
ca
nt
    
    
    
    
    
    
    
   P
CT
: A
UC
, 0
.87
 (9
5%
 C
I, 
0.8
4-
0.9
0)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
se
ns
iti
vit
y, 
0.8
1; 
sp
ec
ifi
cit
y, 
0.7
9
Yu
an
 e
t a
l.,
 2
01
33
8
    
    
  S
AA
, C
RP
    
    
    
    
    
No
n-
sp
ec
ifi
ed
    
    
    
    
    
    
    
    
9 
st
ud
ie
s, 
82
3 
pa
tie
nt
s 
    
    
    
    
    
    
    
    
    
    
    
 N
eo
na
te
s 
    
    
    
    
    
    
    
  S
ig
ni
fic
an
t 
    
    
    
    
    
    
  S
AA
: A
UC
, 0
.90
 (
95
%
 C
I, 
0.8
7-
0.9
3)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  s
en
si
tiv
ity
, 0
.84
; s
pe
ci
fic
ity
, 0
.89
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  C
RP
: A
UC
, 0
.92
 (
0.8
7-
0.9
3)
; (
95
%
 C
I, 
to
); 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  s
en
si
tiv
ity
, 0
.67
; s
pe
ci
fic
ity
, 0
.92
Lv
 e
t a
l.,
 2
01
43
9
    
    
    
    
 T
NF
-α
    
    
    
    
    
0.1
8-
20
00
0 
pg
/m
L 
    
    
    
    
    
    
    
  1
5 
ar
tic
ol
i e
 2
3 
tr
ia
ls
    
    
    
    
    
    
    
    
    
    
    
    
Ne
on
at
es
    
    
    
    
    
    
    
   S
ig
ni
fic
an
t  
    
    
    
    
    
    
    
   T
NF
-α
in
 a
rt
ic
le
s: 
AU
C,
 0
.74
 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
   (
95
%
 C
I, 
0.7
0-
0.7
8)
; s
en
si
tiv
ity
, 0
.66
; s
pe
ci
fic
ity
, 0
.76
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
 T
NF
-α
in
 tr
ia
ls
: A
UC
, 0
.87
 (
95
%
 C
I, 
0.8
5-
0.8
9)
; 
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
  s
en
si
tiv
ity
, 0
.68
; s
pe
ci
fic
ity
, 0
.73
Zh
ou
 e
t a
l.,
 2
01
54
0   
    
    
    
 IL
-8
    
    
    
    
    
    
 0.
6-
30
0 
pg
/m
L 
    
    
    
    
    
    
    
   8
 s
tu
di
es
, 5
48
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
    
 N
eo
na
te
s 
    
    
    
    
    
    
    
  S
ig
ni
fic
an
t  
    
  I
L-
8: 
AU
C,
 0
.89
 (
±
0.0
5)
; s
en
si
tiv
ity
, 0
.78
; s
pe
ci
fic
ity
, 0
.83
Xu
 e
t a
l.,
 2
01
64
1   
    
    
    
    
 C
RP
    
    
    
    
    
    
  2
.5-
21
.0 
m
g/
L 
    
    
    
    
    
    
    
  3
1 
st
ud
ie
s, 
56
98
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
   N
eo
na
te
s 
    
    
    
    
    
    
    
  S
ig
ni
fic
an
t  
    
  C
RP
: A
UC
, 0
.85
 (
±
0.0
5)
; s
en
si
tiv
ity
, 0
.69
; s
pe
ci
fic
ity
, 0
.77
Sh
i e
t a
l.,
 2
01
64
2   
    
    
    
  n
CD
64
    
1.6
3-
61
36
 (
ar
bi
tr
ar
y m
ea
su
re
 u
ni
t)
    
    
   1
7 
st
ud
ie
s, 
34
78
 p
at
ie
nt
s 
    
    
    
    
    
    
    
    
    
    
   N
eo
na
te
s 
    
    
    
    
    
    
    
  S
ig
ni
fic
an
t  
    
  C
RP
: A
UC
, 0
.87
 (
±
0.0
2)
; s
en
si
tiv
ity
, 0
.77
; s
pe
ci
fic
ity
, 0
.74
Po
nt
re
lli
 e
t a
l.,
 2
01
74
3   
    
  P
CT
    
    
    
    
    
    
0.2
8-
14
.0 
ng
/m
L 
    
    
    
    
    
    
    
17
 s
tu
di
es
, 1
40
8 
pa
tie
nt
s 
    
    
    
    
    
    
    
    
 P
ed
ia
tr
ic
 p
op
ul
at
io
n 
    
    
    
    
No
n-
si
gn
ifi
ca
nt
 P
CT
: A
UC
, n
on
-c
al
cu
la
te
d;
 s
en
si
tiv
ity
, 0
.85
; s
pe
ci
fic
ity
, 0
.54
AU
C,
 A
re
a 
Un
de
r t
he
 C
ur
ve
; I
L-
6,
 in
te
rle
uk
in
 6
; I
L-
8,
 in
te
rle
uk
in
 8
; I
Q
R,
 in
te
rq
ua
rt
ile
 ra
ng
e;
 L
BP
, l
ip
op
ol
ys
ac
ch
ar
id
e-
bi
nd
in
g 
pr
ot
ei
n;
 n
CD
64
, n
eu
tr
op
hi
l C
D6
4;
 P
CT
, p
ro
ca
lc
ito
ni
n;
 C
RP
, C
 re
ac
tiv
e 
pr
ot
ei
n;
 S
AA
, S
er
um
 A
m
ylo
id
 A
; s
uP
AR
, s
er
um
 s
ol
ub
le
 u
ro
ki
na
se
-ty
pe
 p
la
sm
in
og
en
 a
ct
iva
to
r r
ec
ep
to
r; 
sT
RE
M
-
1,
 s
ol
ub
le
 tr
ig
ge
rin
g 
re
ce
pt
or
 e
xp
re
ss
ed
 o
n 
m
ye
lo
id
 c
el
ls
-1
; T
NF
-α
, t
um
or
 n
ec
ro
si
s 
fa
ct
or
-α
.No
n c
mm
erc
ial
us
e o
nly
[page 46]                                                       [Emergency Care Journal 2017; 13:6877]
measurement of circulating infective bio-
markers is one of the most promising tools
that have recently emerged. The term bio-
marker is conventionally used to define a
measurable analyte, which can improve diag-
nostic accuracy, simplify complex clinical
algorithms and improve the clinical decision-
making.14 In the specific area of sepsis, an
ideal marker should allow early diagnosis
(i.e., be measurable before or at the appear-
ance of clinical signs), be very sensitive and
specific also for the differential diagnosis of
infectious and non-infectious forms of sys-
temic dysfunction, permit to obtain valid clin-
ical information about the course and progno-
sis of sepsis and, last but not least, provide
reliable indications for guiding antibiotic
therapy.
Search strategy
An electronic search strategy was con-
ducted on the three major scientific databas-
es (Medline with PubMed interface, Scopus
and Web of Science),15 using the keywords
sepsis AND biomarker (s) AND meta-
analysis, without language and/or date
restrictions (Figure 1). The existence of
additional meta-analyses published in sci-
entific journals was then verified by accu-
rately checking the list of bibliographic ref-
erences. The title, summary and, when nec-
essary, the full text of the documents identi-
fied with the search criteria were independ-
ently evaluated by two authors (GL and
MM), with exclusion of all meta-analyses in
which the diagnostic performance of bio-
markers for diagnosing sepsis and manag-
ing antibiotic therapy was unavailable. The
following information was reported, when
available, for all selected documents: (A)
clinical setting; (B) number of studies
included in the meta-analysis; (C) total
number of patients included in the meta-
analysis and characteristics of the studies
(i.e., prospective and/or case-control); (D)
heterogeneity of studies (significant,
>50%); (E) diagnostic performance
expressed in terms of area under the curve
(AUC), sensitivity and specificity, or clini-
cal efficacy in case of biomarker-guided
antibiotic therapy; (F) diagnostic cut-offs.
The consensus document was drafted
after identification by both scientific soci-
eties SIBioC (Italian Society of Clinical
Biochemistry and Laboratory Medicine) and
AcEMC (Academy of Emergency Medicine
and Care) of eight members each, to whom
a questionnaire was administered. The con-
sensus members were asked to rate some
recommendations about the use of biomark-
ers for diagnosing sepsis and managing
antibiotic therapy in the ED. In accordance
with the National Guidelines Program
(PNLG) (16), the recommendations were
then formulated with a grading system
based on the strength of the recommendation
expressed in letters (from A to E), as sum-
marized in Table 1. The questionnaire con-
taining the recommendations was sent by e-
mail to all participants, who were asked to
rate each recommendation from A to E, as in
Table 1. The final grade of recommendation
was expressed as the average (and standard
deviation; SD) of individual opinions after
rating was converted in numeric data (A = 1;
B = 2; C = 3; D = 4; E = 5). A mean score of
<1.5 was rated as grade A, between 1.5 and
<2.5 as grade B, between 2.5 and <3.5 as
grade C, between 3.5 and <4.5 as grade D
and ≥4.5 as grade E.
Results and Discussion
The systematic search, carried out
according to the above-mentioned criteria,
allowed identifying 79 documents after
duplicates elimination. Forty-six items were
excluded since they were not relevant for
the purpose of this document (Figure 1). Six
out of the 33 remaining documents con-
tained data about the use of biomarkers for
monitoring antibiotic therapy in sepsis
patients (all about procalcitonin, PCT),
whereas 27 dealt with the use of biomarkers
for diagnosing sepsis. Eight of these docu-
ments were carried out in pediatric popula-
tions, the remaining 19 in adult populations.
The agreement between the two authors
who analyzed the search products was
100%. Documents about the use of bio-
markers for diagnosing sepsis in the adult17-
35 and pediatric populations (added for com-
prehensiveness)36-43 are summarized in
Table 2.17-43 The documents containing data
about biomarker-guided antibiotic therapy
is summarized in Table 3.44-49 The hetero-
geneity of the studies was found to be sig-
nificant in almost all meta-analyses. In par-
ticular, only 4 of the 6 meta-analyses about
biomarker-guided antibiotic therapy were
not characterized by significant heterogene-
                             Opinion Report
Table 3. Meta-analyses about the biomarker-guided antibiotic therapy.
Authors                     Biomarkers     Studies and population                  Setting             Heterogeneity                            Results
Kopterides et al., 201044          PCT                   7 studies, 1131 patients                      Intensive care                  Significant                              Reduction of 4.2 days 
                                                                                                                                                                                                                                           (95% CI, 3.4-5.0) duration 
                                                                                                                                                                                                                                               of antibiotic therapy; 
                                                                                                                                                                                                                                          reduction of 18% antibiotic 
                                                                                                                                                                                                                                                therapy expenditure
Heyland et al., 201145                PCT                    5 studies, 947 patients                       Intensive care              Non-significant                          Reduction of 2.1 days 
                                                                                                                                                                                                                               (95% CI, 1.8-2.5) duration of antibiotic 
                                                                                                                                                                                                                                     therapy; likely economic benefit
Schuetz et al., 201146                PCT                  14 studies, 4467 patients                      Primary care,              Non-significant             Reduction of 29% (95% CI, 15-37%)
                                                                                                                                        emergency department,                                                   duration of antibiotic therapy
                                                                                                                                                 intensive care                                                                  (34%; 95% CI, 15-53 for
                                                                                                                                                                                                                                           emergency department)
Soni et al., 201347                       PCT            18 studies, number of patients               Intensive care              Non-significant          Reduction of 2.0 days (95% CI, 1.5-2.6)
                                                                                           unavailable                                                                                                                       duration of antibiotic therapy
Prkno et al., 201348                    PCT                   7 studies, 1075 patients                      Intensive care              Non-significant                             Reduction of 27% 
                                                                                                                                                                                                                                                    (95% CI, 5-53%) 
                                                                                                                                                                                                                                        duration of antibiotic therapy
Andriolo et al., 201749               PCT                  10 studies, 1215 patients             Unselected population          Significant                              Reduction of 1.3 days 
                                                                                                                                                                                                                                                    (95% CI, 0.6-2.0) 
                                                                                                                                                                                                                                        duration of antibiotic therapy
PCT, procalcitonin; CI, confidence interval.
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ity. The main source of heterogeneity in
studies included in the different meta-analy-
ses was attributable to the use of different
diagnostic cut-offs (Table 2). In most cases,
the meta-analyses included a large number
of prospective studies (Table 2).
The largest number of meta-analyses on
the use of biomarkers for diagnosing sepsis
in adults contained data about PCT (10
overall) (Table 4). Six meta-analyses con-
tained information about presepsin and
three meta-analyses contained data about C
reactive protein (CRP). Information about
interleukin 6 (IL-6), lipopolysaccharide-
binding protein (LBP), neutrophil CD64
(nCD64) and soluble triggering receptor
expressed on myeloid cells-1 (sTREM-1)
was available in two meta-analyses for each
of these markers, whereas only one meta-
analysis contained data about soluble uroki-
nase-type plasminogen activator receptor
(suPAR). The most favorable diagnostic
performance, expressed as area under the
curve (AUC), was observed for nCD64,
PCT, sTREM-1, suPAR and presepsin,
although none of these biomarkers reached
a diagnostic efficiency close to 100% (Table
4). The AUC of IL-6, LBP and CRP in the
adult population were overall lower than
                                                                                                                Opinion Report
Table 4. Summary of individual biomarker performance research for diagnosing sepsis in
adult populations. 
Biomarker       Meta-analyses (n)    Range AUC       Range sensitivity   Range specificity
IL-6                                            2                             0.79-0.80                        0.68-0.72                          0.73-0.73
LBP                                            2                             0.68-0.71                        0.62-0.70                          0.56-0.70
nCD64                                       2                             0.95-0.96                        0.76-0.87                          0.85-0.93
PCT                                           10                            0.78-1.00                        0.71-1.00                          0.61-0.88
CRP                                            3                             0.71-0.77                        0.75-0.91                          0.36-0.67
Presepsin                                 6                             0.86-0.89                        0.77-0.85                          0.73-0.88
sTREM-1                                   2                             0.85-0.87                        0.78-0.83                          0.68-0.78
suPAR                                        1                                  0.82                                 0.80                                   0.80
AUC, area under the curve; IL-6, interleukin 6; LBP, lipopolysaccharide-binding protein; nCD64, neutrophil CD64; PCT, procalcitonin; CRP, C
reactive protein; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; suPAR, serum soluble urokinase-type plasminogen acti-
vator receptor.
Table 5. Kinetics of C reactive protein, procalcitonin, presepsin, and suggested cut-off for
ruling out sepsis.
                  Increase (h)         Peak (h)         Half-life (h)       Cut-off for ruling out sepsis
CRP                          12-24                          48-72                           20                                           <10 mg/L
PCT                            2-4                              6-8                          20-24                                       <2.0 mg/L
Presepsin                   2                                 3                              4-5                                    <500-600 pg/mL
CRP, C reactive protein; PCT, procalcitonin.
Table 6. Cumulative recommendations according to the available literature data, and to the opinions of the consensus group.
Recommendation                                                                                                                                                               Score              Strenght
The measurement of biomarkers may be of clinical significance in the diagnostic approach of patients with suspect sepsis             1.56±1.06                        B
In the diagnostic approach of patients with suspect sepsis, biomarker assessment should be:                                                                                                             
         Always available on prescription (24/365)                                                                                                                                                           1.36±1.04                        A
         Free on prescription (i.e., no need to contact the laboratory to agree on the request)                                                                        1.63±0.78                        B
In the diagnostic approach of patients with suspect sepsis, it is advisable to measure                                                                                                                             
         IL-6                                                                                                                                                                                                                               3.88±0.99                        D
         LBP                                                                                                                                                                                                                               4.06±0.83                        D
         nCD64                                                                                                                                                                                                                           3.69±0.92                        D
         PCT                                                                                                                                                                                                                               1.56±0.79                        B
         CRP                                                                                                                                                                                                                               2.00±0.94                        B
         Presepsin                                                                                                                                                                                                                    2.50±1.06                        C
         sTREM-1                                                                                                                                                                                                                      3.81±0.88                        D
         suPAR                                                                                                                                                                                                                           3.50±0.79                        D
The biomarker cut-off should be selected:                                                                                                                                                                                                            
         Favoring a high negative predictive value, for ruling out a diagnosis of sepsis                                                                                         1.75±0.83                        B
         Favoring a high positive predictive value, for enabling a diagnosis of sepsis                                                                                            2.75±0.90                        C
Test results should always be interpreted according to clinical data                                                                                                                   1.00±0.00                        A
For PCT assessment immunoassays with better functional sensitivity (i.e., ≤0.05 ng/mL) should be preferred                                     1.63±0.60                        B
The assessment of a second biomarker may be useful when the result of the first biomarker is negative in patients with                2.38±1.11                        B
a strong clinical suspect of sepsis                                                                                                                                                                                        
Due to availability of multiple assays, short turnaround time and low costs, CRP should be the second sepsis biomarker                  2.31±1.31                        B
Serial testing in patients with sepsis should be defined according to biomarker kinetics                                                                             1.38±0.99                        A
(repeated testing not early that 18-24 hours for PCT and CRP, not earlier than 5 hours for presepsin)                                                          
Serial PCT testing can be used for monitoring antibiotic therapy in patients with sepsis                                                                               1.50±1.00                        B
Serial testing for monitoring antibiotic therapy should be defined according to biomarker kinetics                                                          1.63±1.05                        B
(i.e., repeated testing not early that 18-24 hours for PCT)                                                                                                                                            
The test panel in patients with sepsis should also include the assessment of lactic acid                                                                              1.50±0.79                        B
IL-6, interleukin 6; LBP, lipopolysaccharide-binding protein; nCD64, neutrophil CD64; PCT, procalcitonin; CRP, C reactive protein; sTREM-1, soluble triggering receptor expressed on myeloid cells-1; suPAR, serum sol-
uble urokinase-type plasminogen activator receptor.
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those of the other biomarkers. The values of
sensitivity and specificity were globally
aligned with those of the AUCs (Table 4).
As regards the five biomarkers display-
ing the better diagnostic performance (i.e.,
nCD64, PCT, presepsin, sTREM-1 and
suPAR), some additional considerations
may be necessary about the analytical tech-
nology used for their assessment. Only for
PCT and presepsin automatic or semi-auto-
matic immunoassays are currently available
for urgent measurement, whereas only man-
ual enzyme-linked immunosorbent assay
(ELISA) are available for sTREM-1 and
suPAR, thus making their assessment rather
impractical for rapid diagnosis of sepsis.50 A
similar consideration can be made for
nCD64. This biomarker can only be
assessed with flow-cytometry and specific
kits, so that the measurement of nCD64 is
currently incompatible with an urgent diag-
nosis of sepsis in most clinical laborato-
ries.50 Although PCT can now be measured
with a wide range of commercial methods
based on different analytical techniques
(immunochemiluminescence, immunofluo-
rescence, immunoturbidimetry), and so
potentially adaptable to the vast majority of
clinical and immunochemical analyzers
available in clinical laboratories,51 the quan-
tification of presepsin is now only possible
using a single point-of-care (POC) analyzer.
It is also noteworthy that the analytical per-
formance of the PCT immunoassays cur-
rently commercially available may substan-
tially differ. The techniques with better sen-
sitivity are usually characterized by a func-
tional sensitivity ≤0.05 ng/mL (51) and are
hence more suited for monitoring of antibi-
otic therapy. The in vivo kinetics of PCT,
presepsin and CRP in patients with sepsis
are described in Table 5.52
A single meta-analysis could be
identified in pediatric populations for each
of serum amyloid A (SAA), tumor necrosis
factor (TNF)-α and interleukin 8 (IL-8)
(Table 3), so that translation of diagnostic
performance in adults is unadvisable
according to the search criteria defined in
this consensus document.
As regards monitoring of antibiotic
therapy, all the six meta-analyzes identified
by our literature search dealt with PCT. In
all cases the serial assessment of this bio-
marker allowed to significantly reducing
the duration of antibiotic therapy (Table 3).
In the two meta-analyses also evaluating
economic issues, PCT-guided antibiotic
therapy allowed to reduce the overall cost
of patient management. Unfortunately, little
evidence is currently available about the
effectiveness of PCT-guided antibiotic ther-
apy to narrow the spectrum of antibiotic
therapy. Notably, a retrospective study
including more than 20000 patients hospi-
talized in 107 UTI failed to show significant
benefits (in terms of outcome or duration of
therapy) in patients with serial PCT test-
ing.53
Recommendations
According to the available literature
data, and to the opinions of the consensus
group, the following cumulative recom-
mendations can be made (the score reflects
the mean and SD of individual opinions) as
in Table 6.
Conclusions
The World Health Organization (WHO)
has recently published a firm resolution
mandating that sepsis should be considered
a global health priority.54-57 Among the var-
ious recommended actions for reducing the
global burden of this time-critical medical
emergency, the WHO urges member states
to develop evidence-based strategies for
early diagnosis and appropriate treatment in
order to avert deterioration, improve out-
comes and ensure patient safety. Our con-
sensus document should hence be seen as a
timely reaction to the WHO resolution.
The cumulative opinions of the mem-
bers of this consensus document allowed to
define three grade A recommendations (i.e.,
highly recommended indications), substan-
tially in line with those previously pub-
lished in our country and complementing
the indications about blood culture (55-57),
but are now supported by a more systematic
and recent collection of evidence analyzed
by means of an interdisciplinary consensus
between two scientific societies of
Emergency (AcEMC) and Laboratory
(SIBioC) Medicine.
The three grade A recommendations
entailed the ordering modality (biomarkers
always available on prescription), the prac-
tical use (results should be interpreted
according to clinical information) and test
ordering defined according to biomarker
kinetics. Additional grade B recommenda-
tions (i.e., potentially valuable indications)
entailed general agreement that biomarkers
assessment may be of clinical value in the
diagnostic approach of ED patients with
suspect sepsis, suggestion for combined
assessment of PCT and CRP, free availabil-
ity of the selected biomarker(s) on prescrip-
tion, adoption of diagnostic threshold prior-
itizing a high negative predictive value giv-
ing preference to more analytically sensi-
tive techniques, along with the potential
clinical usefulness of measuring PCT for
monitoring antibiotic treatment, with serial
testing defined according to biomarker
kinetics. PCT and CRP were the two bio-
markers, which received the largest consen-
sus as biomarkers of sepsis (grade B recom-
mendation), and a grade B recommendation
was also reached for routine assessment of
blood lactate. The assessment of biomarkers
other than PCT and CRP was discouraged,
with the exception of presepsin for which
substantial uncertainty in favor or against
remained.
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